Compare Lupin with STRIDES PHARMA SCIENCE - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

LUPIN vs STRIDES PHARMA SCIENCE - Comparison Results

LUPIN     Change

Lupin is a leading pharmaceutical company with a strong presence in anti-infective, cardiovascular and asthma. Apart from having a strong domestic presence, the company markets its products in the regulated markets of the US and Europe and semi-regul... More

STRIDES PHARMA SCIENCE 
   Change

Strides Arcolab is an Indian pharmaceutical company headquartered at Bangalore. The company is primarily involved in two businesses notably the pharma business and the specialized sterile products business branded as Agila. This segment focuses large... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    LUPIN STRIDES PHARMA SCIENCE LUPIN/
STRIDES PHARMA SCIENCE
 
P/E (TTM) x 46.3 42.1 110.0% View Chart
P/BV x 4.3 2.0 216.7% View Chart
Dividend Yield % 0.5 0.2 205.7%  

Financials

 LUPIN   STRIDES PHARMA SCIENCE
EQUITY SHARE DATA
    LUPIN
Mar-20
STRIDES PHARMA SCIENCE
Mar-18
LUPIN/
STRIDES PHARMA SCIENCE
5-Yr Chart
Click to enlarge
High Rs8821,147 76.9%   
Low Rs505642 78.7%   
Sales per share (Unadj.) Rs339.4317.2 107.0%  
Earnings per share (Unadj.) Rs-5.97.8 -75.8%  
Cash flow per share (Unadj.) Rs15.525.1 61.7%  
Dividends per share (Unadj.) Rs6.002.00 300.0%  
Dividend yield (eoy) %0.90.2 386.9%  
Book value per share (Unadj.) Rs276.7274.3 100.9%  
Shares outstanding (eoy) m453.0089.50 506.1%   
Bonus / Rights / Conversions ESOPESOP-  
Price / Sales ratio x2.02.8 72.5%   
Avg P/E ratio x-116.6114.0 -102.3%  
P/CF ratio (eoy) x44.835.7 125.6%  
Price / Book Value ratio x2.53.3 76.8%  
Dividend payout %-100.925.5 -395.7%   
Avg Mkt Cap Rs m314,20180,058 392.5%   
No. of employees `00018.32.5 730.0%   
Total wages/salary Rs m29,8684,341 688.1%   
Avg. sales/employee Rs Th8,400.611,325.8 74.2%   
Avg. wages/employee Rs Th1,632.01,731.4 94.3%   
Avg. net profit/employee Rs Th-147.2280.1 -52.6%   
INCOME DATA
Net Sales Rs m153,74828,394 541.5%  
Other income Rs m4,838941 514.3%   
Total revenues Rs m158,58529,334 540.6%   
Gross profit Rs m24,8493,965 626.6%  
Depreciation Rs m9,7021,540 629.8%   
Interest Rs m3,6301,962 185.0%   
Profit before tax Rs m16,3551,403 1,165.5%   
Minority Interest Rs m40-   
Prior Period Items Rs m39-168 -23.5%   
Extraordinary Inc (Exp) Rs m-7,521-436 1,725.7%   
Tax Rs m11,57197 11,892.2%   
Profit after tax Rs m-2,694702 -383.7%  
Gross profit margin %16.214.0 115.7%  
Effective tax rate %70.86.9 1,020.3%   
Net profit margin %-1.82.5 -70.9%  
BALANCE SHEET DATA
Current assets Rs m154,13224,836 620.6%   
Current liabilities Rs m92,25218,993 485.7%   
Net working cap to sales %40.220.6 195.6%  
Current ratio x1.71.3 127.8%  
Inventory Days Days8271 115.6%  
Debtors Days Days129113 114.0%  
Net fixed assets Rs m89,08234,289 259.8%   
Share capital Rs m906895 101.2%   
"Free" reserves Rs m124,46123,651 526.2%   
Net worth Rs m125,36724,546 510.8%   
Long term debt Rs m17,93315,513 115.6%   
Total assets Rs m249,83965,437 381.8%  
Interest coverage x5.51.7 321.0%   
Debt to equity ratio x0.10.6 22.6%  
Sales to assets ratio x0.60.4 141.8%   
Return on assets %0.44.1 9.2%  
Return on equity %-2.12.9 -75.1%  
Return on capital %8.76.9 126.6%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m51,45015,697 327.8%   
Fx outflow Rs m19,470735 2,647.6%   
Net fx Rs m31,98014,962 213.7%   
CASH FLOW
From Operations Rs m14,6881,871 785.2%  
From Investments Rs m11,0705,826 190.0%  
From Financial Activity Rs m-8,906-10,157 87.7%  
Net Cashflow Rs m16,853-2,615 -644.5%  

Share Holding

Indian Promoters % 46.6 27.7 168.2%  
Foreign collaborators % 0.2 0.0 -  
Indian inst/Mut Fund % 11.3 37.8 29.9%  
FIIs % 31.9 8.6 370.9%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.1 25.9 39.0%  
Shareholders   98,259 56,241 174.7%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare LUPIN With:   NATCO PHARMA  PANACEA BIOTECH  GLENMARK PHARMA  GSK PHARMA  FRESENIUS KABI ONCO.  

Compare LUPIN With:   MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex, Nifty End Flat; Asian Paints, UPL & ITC Among Top Gainers(Closing)

Indian share markets witnessed volatile trading activity throughout the day today and ended on a flat note.

Related Views on News

STRIDES PHARMA SCIENCE Announces Quarterly Results (3QFY21); Net Profit Down 46.4% (Quarterly Result Update)

Feb 5, 2021 | Updated on Feb 5, 2021

For the quarter ended December 2020, STRIDES PHARMA SCIENCE has posted a net profit of Rs 621 m (down 46.4% YoY). Sales on the other hand came in at Rs 8 bn (up 13.6% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

LUPIN 2019-20 Annual Report Analysis (Annual Result Update)

Dec 7, 2020 | Updated on Dec 7, 2020

Here's an analysis of the annual report of LUPIN for 2019-20. It includes a full income statement, balance sheet and cash flow analysis of LUPIN. Also includes updates on the valuation of LUPIN.

LUPIN Announces Quarterly Results (2QFY21); Net Profit Up 271.3% (Quarterly Result Update)

Nov 6, 2020 | Updated on Nov 6, 2020

For the quarter ended September 2020, LUPIN has posted a net profit of Rs 2 bn (up 271.3% YoY). Sales on the other hand came in at Rs 38 bn (down 12.0% YoY). Read on for a complete analysis of LUPIN's quarterly results.

STRIDES PHARMA SCIENCE Announces Quarterly Results (1QFY21); Net Profit Up 184.5% (Quarterly Result Update)

Aug 20, 2020 | Updated on Aug 20, 2020

For the quarter ended June 2020, STRIDES PHARMA SCIENCE has posted a net profit of Rs 1 bn (up 184.5% YoY). Sales on the other hand came in at Rs 8 bn (up 14.0% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

LUPIN Announces Quarterly Results (1QFY21); Net Profit Down 64.2% (Quarterly Result Update)

Aug 18, 2020 | Updated on Aug 18, 2020

For the quarter ended June 2020, LUPIN has posted a net profit of Rs 1 bn (down 64.2% YoY). Sales on the other hand came in at Rs 35 bn (down 20.2% YoY). Read on for a complete analysis of LUPIN's quarterly results.

More Views on News

Most Popular

Is Intraday Trading For You?(Fast Profits Daily)

May 13, 2021

Do you think you have what it takes to be an intraday trader? Find out in this video.

My Secret to Find Breakthrough Stocks(Fast Profits Daily)

May 7, 2021

I've used this trading technique for many years with great success. I'm sharing it with you today.

Are the Stock Markets Deaf to Covid Agony?(Profit Hunter)

May 6, 2021

Why are markets discounting the economic impact of Covid?

The Key to Profit from India's EV Revolution(Profit Hunter)

May 7, 2021

Stocks you must consider investing in before buying your first electric vehicle.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

LUPIN SHARE PRICE


May 14, 2021 (Close)

TRACK LUPIN

COMPARE LUPIN WITH

MARKET STATS